Kevin M. Brennan sold $1,774 of XLO
SVP, FINANCE AND ACCOUNTING at Xilio Therapeutics, Inc.. 1,803 shares at an average of $0.98, traded Jan 2, 2025, filed Jan 3, 2025.
Score components
- +15RoleOfficer
- 0Trade size$2k at market
- +10Share of holdings soldSold 36% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-000404, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 1, 2025 | MOption exercise Common Stock10b5-1 | +5,000 | - | - | 5,000 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common stock10b5-1 | -1,803 | $0.98 | $1,774 | 3,197 | Jan 3, 2025 |
| Jan 1, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -5,000 | $0.00 | $0 | 15,000 | Jan 3, 2025 |
| Jan 1, 2025 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +60,000 | $0.00 | $0 | 60,000 | Jan 3, 2025 |
Related signals
Other insiders at Xilio Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | XLObuy Xilio Therapeutics, Inc. | Rene Russo PRESIDENT AND CEO | $25k 36,289 shares | +15% | |
| 5Weak | Xilio Therapeutics, Inc. | Christopher James Frankenfield Chief Financial Officer | $6,841 6,954 shares | -36% | |
| 38Weak | XLObuy Xilio Therapeutics, Inc. | Gilead Sciences, Inc. owner | $1.8M 1,759,978 shares | +24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.